Regulatory approval

Published by the Health Canada.

Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.

This is written in the approval document as:

ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).

Citation

Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Sensitivity (+)	CD30 +	Angioimmunoblastic T-Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Sensitivity (+)	CD30 +	Peripheral T-Cell lymphoma, NOS	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone